-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, G+z935cFagkoaA4ahRMk/dFC17CHIyCjRDT7QOmbVeFbpDRNySDSrXqQQCVjNgrV pLN95RykzkSQI6W3RvYy+A== 0000000000-08-006224.txt : 20080320 0000000000-08-006224.hdr.sgml : 20080320 20080204130514 ACCESSION NUMBER: 0000000000-08-006224 CONFORMED SUBMISSION TYPE: UPLOAD PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20080204 FILED FOR: COMPANY DATA: COMPANY CONFORMED NAME: CELL THERAPEUTICS INC CENTRAL INDEX KEY: 0000891293 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 911533912 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: UPLOAD BUSINESS ADDRESS: STREET 1: 501 ELLIOTT AVE W STREET 2: STE 400 CITY: SEATTLE STATE: WA ZIP: 98119 BUSINESS PHONE: 2062707100 MAIL ADDRESS: STREET 1: 501 ELLIOTT AVE W STREET 2: STE 400 CITY: SEATTLE STATE: WA ZIP: 98119 PUBLIC REFERENCE ACCESSION NUMBER: 0001193125-07-057204 LETTER 1 filename1.pdf begin 644 filename1.pdf M)5!$1BTQ+C0-)>+CS],-"C8@,"!O8FH@/#PO3&EN96%R:7IE9"`Q+TP@-S8Y M."]/(#@O12`S-3,Y+TX@,2]4(#7!E+U!A9V4^/@UE;F1O8FH-.2`P(&]B:CP\+T9O;G0\/"]45#(@,3`@,"!2 M+U14-"`Q,B`P(%(^/B]0I86I&Z67US M;IUNNVVVUC33Z?9!*].Q6EGRR%+2_'T!D+K8SC:9F#`)$`<'%^;##QL)SZ?% M3;;XD&4*)&2[A53@XR\NJ0]QHKP4LL/"AV?\RPKZ>%T(<+*_472E)R/([A;B M4UY6L.F:(\2^]/DX^\[JH>#ZGN_[$5V@O"0BZ77QIP#[\Z"_MGW>OCFN]+T( MK13JB'#)0B24[Z_`^2O[2%==HKAV(UG#2JCV<].7)UA[<%/E==&<*K%:-:#3D]1:FX`AU0)#<021,Z^W!67F2'$LO%75YZMJ\*YL:OHC' MMJR+\L@WI%ZD(DP>9L38JR$ZE3`5>87>R6^)TJ^[78D`B`[76([Y--RL1FY6 M!LX+![(1".TKL8$T'L2B*IJ>0,3:CTI$*Z]7/[(_$0K=?G#%DXRH= M7:4S5RE>3P%7]$4."V1[S8RG(C^2.U2CC(6&(5H*-CLMX.PY,^=4O8]+Q==AI"WV?Y/(*IZI0MI(W.NZ[2 M2WC"W"4"*<)>$I"N),;XK6JV/66:BG>P,T/3F8')++,TX9<6_V_Z>T#2%3;. MK4:`D:@J8HK%EC]S9"411[.%C(444<'?F"HC&FQN<%$-?CQV;SQT[T/3'FRS M2M_]B<0P$KNFM5*WU_;XH3P5><4W2VP):4.91?^'SENXK[=Z"W>ZT(>ONH5` M+D&19ZY1G`UH>($J&FGGF2(8$H+Y#`2#`'S&R=+IMGJ#1TWW2&S5=$;EU&X! ME[EHRV9KD6STL2,;+*&SO@K&$<,=*BQ(#H,>-A'%WG[!T?%HTIL7#6YZ,C:1W=42X^M3@QJ9T":KR` MZH>;*1`T0\F?_VUWYS.?R9W%$"9XVY.&??ZBH6@.QTIWR';3M]!J4R3H+XRF M++TS%%]*V_NOT.P`WXX4RYFZ-Q!X#]4!STPPES7W3?4J#'>5SJ<%IK< M7&,%+0%?;866-&;?*Q(4"F]TX./SQH;G`.93+9Q-M?G_#E?/^#7,C^0B19B- M<7(&@F';.?,XQ)//84>!^,=,)'VQ/:*=?*U-7(HI"(G=D0OKO3>+9:H;(%Q2 M^#P0PLL-GPY^1WBUP36ZV)\9W1HCNSDZ&*/8S:-0ER/&$.K.]R_(OL\6_PDP M`+UL0B4*#0IE;F1S=')E86T-96YD;V)J#3$R(#`@;V)J/#PO4W5B='EP92]4 M7!E+T9O;G0^/@UE;F1O M8FH-,3,@,"!O8FH\/"]3=&5M5B`X,B]&;VYT3F%M92]4:6UE'1'4W1A M=&4O4T$@9F%LFMC.60B/SX*/'@Z>&UP;65T82!X;6QN#IX;7!T:STB,RXQ+3&UL;G,Z>&%P/2)H='1P.B\O;G,N861O8F4N M8V]M+WAA<"\Q+C`O(CX*("`@("`@("`@/'AA<#I#&%P.D-R96%T;W)4;V]L/E!38W)I<'0U+F1L;"!697)S:6]N(#4N,BXR M/"]X87`Z0W)E871O&UL.FQA;F<](G@M9&5F875L="(^36EC&%P34TZ26YS=&%N8V5)1#YU=6ED M.C,X.&(Q,S-D+6$W,34M-#)E.2UA.3)E+3`Q.#$S9#9E.&5B.3PO>&%P34TZ M26YS=&%N8V5)1#X*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@(#PO -----END PRIVACY-ENHANCED MESSAGE-----